RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-6.58%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.73B
AUM Growth
+$3.73B
(-11%)
Cap. Flow
-$74.6M
Cap. Flow
% of AUM
-2%
Top 10 Holdings %
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
24
Closed
9
Top Buys
| 1 |
Boston Scientific
BSX
|
$47.1M |
| 2 |
Penumbra
PEN
|
$33.3M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$25M |
| 4 |
Immunovant
IMVT
|
$24.7M |
| 5 |
Amgen
AMGN
|
$18.3M |
Top Sells
| 1 |
argenx
ARGX
|
$44.7M |
| 2 |
Spyre Therapeutics
SYRE
|
$40.1M |
| 3 |
Insulet
PODD
|
$28.5M |
| 4 |
CONMED
CNMD
|
$27.9M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.7M |
Sector Composition
| 1 | Healthcare | 97.08% |
| 2 | Consumer Staples | 1.17% |
| 3 | Industrials | 0.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OKUR
76
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $8.71M | 0.23% | 1,143,185 | – | – |
|
77
Pliant Therapeutics
PLRX
$101M
| $8.52M | 0.23% | 491,221 | – | – |
|
78
Pulmonx
LUNG
$69.7M
| $6.74M | 0.18% | 652,400 | – | – |
|
|
ICVX
79
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $6.73M | 0.18% | 868,409 | – | – |
|
80
Sagimet Biosciences
SGMT
$244M
| $6.5M | 0.17% | +738,355 | New | +$6.5M |
|
81
Aura Biosciences
AURA
$389M
| $6.48M | 0.17% | 722,896 -296,861 | -29% | -$2.66M |
|
|
SPRB
82
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $6.17M | 0.17% | 2,728,125 | – | – |
|
83
Relay Therapeutics
RLAY
$619M
| $5.67M | 0.15% | 673,966 | – | – |
|
84
MacroGenics
MGNX
$112M
| $5.49M | 0.15% | 1,178,796 +55,700 | +5% | +$260K |
|
85
Novavax
NVAX
$1.21B
| $4.69M | 0.13% | 647,700 +111,000 | +21% | +$804K |
|
86
Mersana Therapeutics
MRSN
$36.5M
| $4.32M | 0.12% | 3,403,133 | – | – |
|
87
Cytokinetics
CYTK
$4.23B
| $3.96M | 0.11% | 134,252 -313,348 | -70% | -$9.23M |
|
88
Aurinia Pharmaceuticals
AUPH
$1.58B
| $3.73M | 0.1% | 479,540 | – | – |
|
89
Fulcrum Therapeutics
FULC
$351M
| $3.23M | 0.09% | 727,673 | – | – |
|
90
Health Catalyst
HCAT
$239M
| $3.11M | 0.08% | 307,500 -622,400 | -67% | -$6.3M |
|
91
Xilio Therapeutics
XLO
$36.3M
| $3.04M | 0.08% | 1,440,759 | – | – |
|
92
Gossamer Bio
GOSS
$562M
| $2.72M | 0.07% | 3,266,960 +2,166,686 | +197% | +$1.8M |
|
93
Beam Therapeutics
BEAM
$1.66B
| $2.68M | 0.07% | 111,430 | – | – |
|
|
VIGL
94
DELISTED
Vigil Neuroscience
VIGL
| $2.54M | 0.07% | 471,958 | – | – |
|
95
Biomea Fusion
BMEA
$116M
| $2.49M | 0.07% | 181,147 -655,751 | -78% | -$9.02M |
|
|
ADAP
96
Adaptimmune Therapeutics
ADAP
$15.6M
| $2.17M | 0.06% | 2,787,845 | – | – |
|
97
ESSA Pharma
EPIX
$11.4M
| $2.09M | 0.06% | 677,005 +13,688 | +2% | +$42.3K |
|
98
Applied Therapeutics
APLT
$71M
| $2.01M | 0.05% | 808,809 +28,018 | +4% | +$69.8K |
|
|
99
Spyre Therapeutics
SYRE
$996M
| $1.67M | 0.04% | 136,556 -3,277,350 | -96% | -$40.1M |
|
100
Leap Therapeutics
LPTX
$12M
| $1.48M | 0.04% | 1,074,517 | – | – |
|